WEDGE CORPORATION released its 2024 annual performance, with a net profit attributable to shareholders of 193 million yuan, a year-on-year increase of 9.17%, and plans to distribute a cash dividend of 0.5 yuan per share
I'm LongbridgeAI, I can summarize articles.WEDGE CORPORATION released its 2024 annual performance, with a net profit attributable to the parent company of 193 million yuan, a year-on-year increase of 9.17%. The company's revenue was 1.079 billion yuan, a year-on-year increase of 9.93%; the net profit excluding non-recurring gains and losses was 160 million yuan, a year-on-year increase of 54.12%. The basic earnings per share were 0.3932 yuan, and it plans to distribute a cash dividend of 0.5 yuan for every 10 shares to shareholders. The company is actively transforming in the pharmaceutical and high-tech fields, obtaining multiple national invention patents, and promoting the recognition of high-tech enterprises
According to the Zhitong Finance APP, WEDGE CORPORATION (000534.SZ) disclosed its 2024 annual report, showing that the company achieved revenue of 1.079 billion yuan during the reporting period, a year-on-year increase of 9.93%; net profit attributable to the parent company was 193 million yuan, a year-on-year increase of 9.17%; net profit excluding non-recurring items was 160 million yuan, a year-on-year increase of 54.12%; and basic earnings per share were 0.3932 yuan. The company plans to distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares to all shareholders.
During the reporting period, the company's pharmaceutical division actively transformed and upgraded in response to new changes in the pharmaceutical industry environment, innovating operations and achieving record-high performance. The company's high-tech division focused on the high-temperature alloy business, seizing strategic opportunities from the rapid development of the aviation engine and gas turbine industries to accelerate industrial layout.
During the reporting period, WEDGE CORPORATION's Microbiology Research Institute successfully obtained authorization for two national invention patents and applied for two national invention patents, laying the foundation for its application for high-tech enterprise recognition. As of December 31, 2024, Inner Mongolia Shuangqi has cumulatively applied for 11 invention patents and has obtained authorization for 10 invention patents. Following its equity investment in Sichuan Anaerobic Biology in 2023, the company further explored the feasibility of deep cooperation with Sichuan Anaerobic Biology during the reporting period